Megesin (Megestrol Acetate)

Megesterol acetate is a synthetic progestogen that binds to progesterone receptors, activating pathways that mimic glucocorticoid activity. This leads to appetite stimulation, reduced inflammatory cytokine release, and direct antineoplastic effects by inhibiting growth of hormone‑sensitive tumor cells.

The appropriate dose of Megesin is determined by the prescribing clinician based on the patient’s condition, weight, and therapeutic goals. Dosage regimens can vary widely, so the prescriber sets the exact amount and schedule.

Safety data for megesterol acetate in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss risks with the patient and consider alternative therapies when possible.

To request Megesin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Megesin’s active ingredient, megesterol acetate, is often compared with other progestins such as medroxyprogesterone acetate. Both share appetite‑stimulating and antineoplastic properties, but megesterol acetate has a stronger glucocorticoid‑like effect, which can result in more pronounced metabolic changes. Choice depends on clinical judgment, patient tolerance, and specific regulatory approvals.

Megesin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging remains sealed until use to maintain stability.

Megesin is administered orally, typically as a tablet or capsule taken with water. The exact timing (e.g., with meals or on an empty stomach) is directed by the prescribing physician based on the individual treatment plan.

Serious adverse events include thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism, adrenal suppression leading to cortisol deficiency, and significant hyperglycemia, especially in patients with pre‑existing diabetes. Prompt medical attention is required if any of these symptoms arise.

Megesin is contraindicated in patients with known hypersensitivity to megesterol acetate or any excipients, in those with active, uncontrolled thromboembolic disease, and in individuals where hormone‑sensitive tumor progression would be worsened unless specifically indicated. Caution is also advised for pregnant or nursing women.